Sugi Predict

Sugi Predict / Compounds / SCHEMBL1604148

SCHEMBL1604148

SCHEMBL1604148

Fc1cccc(CN2CCC(Nc3ncnc4sc(Cl)cc34)CC2)c1

nearest known ligand 0.70

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ HTR2B P41595 1/20 0.70
▸ MEN1 O00255 17/20 0.63
▸ KMT2A Q03164 16/20 0.62
▸ HTT P42858 2/20 0.57
▸ SMN1; SMN2 Q16637 2/20 0.57
▸ RAB9A P51151 2/20 0.52
▸ RXFP1 Q9HBX9 2/20 0.52
▸ MAPK1 P28482 1/20 0.52
▸ LMNA P02545 1/20 0.50
▸ NOD2 Q9HC29 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1604955 0.90 HTR2B (0.70) HTR2BMEN1KMT2AHTTSMN1; SMN2
SCHEMBL1604143 0.90 HTR2B (0.69) HTR2BMEN1KMT2AHTTSMN1; SMN2
Hydrochloric Acid SCHEMBL1920934 0.89 HTR2B (0.68) HTR2BMEN1KMT2AHTTSMN1; SMN2
SCHEMBL13060028 0.89 MEN1 (0.66) HTR2BMEN1KMT2AHTTSMN1; SMN2
SCHEMBL12533525 0.89 MEN1 (0.66) HTR2BMEN1KMT2AHTTSMN1; SMN2
SCHEMBL1604933 0.88 HTR2B (0.65) HTR2BMEN1KMT2AHTTSMN1; SMN2
SCHEMBL1604942 0.86 HTR2B (0.72) HTR2BMEN1KMT2AHTTSMN1; SMN2
SCHEMBL13905660 0.86 HTR2B (0.62) HTR2BMEN1KMT2AHTTSMN1; SMN2
SCHEMBL1605161 0.85 MEN1 (0.64) HTR2BMEN1KMT2AHTTSMN1; SMN2
SCHEMBL1604173 0.85 MEN1 (0.63) HTR2BMEN1KMT2AHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1797099-A1 PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE COMPOUNDS Epix Delaware, Inc. (US) 2007-06-20 — — EP claimed
WO-2006034511-A1 PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE COMPOUNDS EPIX DELAWARE, INC. (US) 2006-03-30 — — WO claimed
US-20050222175-A1 New piperidinylamino-thieno[2,3-D] pyrimidine compounds PGXHEALTH, LLC 2005-10-06 — — US claimed
EP-1622914-B1 NEW PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE COMPOUNDS TROVIS PHARMACEUTICALS LLC (US) 2011-06-01 — — EP disclosed
US-20110082157-A1 Piperidinylamino-Thieno [2,3-D] Pyrimidine Compounds TROVIS PHARMACEUTICALS, LLC 2011-04-07 — — US disclosed
US-20110082157-A1 Piperidinylamino-Thieno [2,3-D] Pyrimidine Compounds TROVIS PHARMACEUTICALS, LLC 2011-04-07 — — US disclosed
US-20110082157-A1 Piperidinylamino-Thieno [2,3-D] Pyrimidine Compounds TROVIS PHARMACEUTICALS, LLC 2011-04-07 — — US disclosed
US-20100280050-A1 Piperidinylamino-Thieno[2,3-D] Pyrimidine Compounds for Treating Fibrosis PGXHEALTH, LLC 2010-11-04 — — US disclosed
US-20100280050-A1 Piperidinylamino-Thieno[2,3-D] Pyrimidine Compounds for Treating Fibrosis PGXHEALTH, LLC 2010-11-04 — — US disclosed
EP-1797099-B1 PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE COMPOUNDS EPIX DELAWARE INC (US) 2010-08-11 — — EP disclosed
US-20100113485-A1 Piperidinylamino-thieno[2,3-D] Pyrimidine Compounds TROVIS PHARMACEUTICALS, LLC 2010-05-06 — — US disclosed
US-7612078-B2 Piperidinylamino-thieno[2,3-D] pyrimidine compounds EPIX DELAWARE, INC. (US) 2009-11-03 — — US disclosed
WO-2009032885-A2 PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE COMPOUNDS FOR TREATING FIBROSIS EPIX DELAWARE, INC. (US) 2009-03-12 — — WO disclosed
EP-1622914-A4 NEW PIPERIDINYLAMINO-THIENO 2,3-D PYRIMIDINE COMPOUNDS EPIX DELAWARE INC (US) 2008-03-12 — — EP disclosed
US-7030240-B2 5-HT receptor antagonist; [1-(2-Fluoro-benzyl)-piperidin-4-yl]-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-amine; treating vascular disorders, angina, migraine, pulmonary hypertension and systemic hypertension PREDIX PHARMACEUTICALS HOLDINGS, INC. (US) 2006-04-18 — — US disclosed
EP-1622914-A2 NEW PIPERIDINYLAMINO-THIENO 2,3-D PYRIMIDINE COMPOUNDS Predix Pharmaceuticals Holdings, Inc. (US) 2006-02-08 — — EP disclosed
US-20050222176-A1 Piperidinylamino-thieno[2,3-D] pyrimidine compounds TROVIS PHARMACEUTICALS, LLC 2005-10-06 — — US disclosed
US-20050222175-A1 New piperidinylamino-thieno[2,3-D] pyrimidine compounds PGXHEALTH, LLC 2005-10-06 — — US disclosed
US-20040248904-A1 New piperidinylamino-thieno[2,3-d] pyrimidine compounds TROVIS PHARMACEUTICALS, LLC 2004-12-09 — — US disclosed
WO-2004089312-A2 NEW PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE COMPOUNDS PREDIX PHARMACEUTICALS HOLDINGS, INC. (US) 2004-10-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100280050-A1 Piperidinylamino-Thieno[2,3-D] Pyrimidine Compounds for Treating Fibrosis HTR2B, HTR3B, HTR1B HTR2B 1/4885MEN1 4310/4885KMT2A 2743/4885
US-20050222175-A1 New piperidinylamino-thieno[2,3-D] pyrimidine compounds HTR5A, HTR3A, HTR1A HTR2B 11/4885MEN1 2389/4885KMT2A 4258/4885
US-20040248904-A1 New piperidinylamino-thieno[2,3-d] pyrimidine compounds HTR5A, HTR2C, HTR1A HTR2B 5/4885MEN1 2833/4885KMT2A 3770/4885
US-20100113485-A1 Piperidinylamino-thieno[2,3-D] Pyrimidine Compounds HTR2B, HTR3B, HTR1B HTR2B 1/4885MEN1 4118/4885KMT2A 3047/4885
US-20050222176-A1 Piperidinylamino-thieno[2,3-D] pyrimidine compounds HTR2B, HTR3B, HTR1B HTR2B 1/4885MEN1 4118/4885KMT2A 3047/4885
US-20110082157-A1 Piperidinylamino-Thieno [2,3-D] Pyrimidine Compounds HTR5A, HTR3A, HTR1A HTR2B 10/4885MEN1 2784/4885KMT2A 4320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.